Helicore Biopharma
helicore.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$2M
1 round on record
Latest round
$2M
Venture round · Apr 2020 · 6 yr ago
Team
1-10
employees, estimated range
Backers
3
Wellington Management, Longitude Capital
The money's age
Long since its last round
77 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 28, 2025
Launched Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions · morningstar.com
Apr 16, 2020
Raised a round Venture round $2M · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2020 | $2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Helicore, LLC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Kevin RussExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Wellington Management 
Longitude Capital 
OrbiMed Overview
Long-Acting Medicines to Transform Metabolic Health. Pioneering long-acting antibody conjugates to deliver quarterly administered, best-in-category therapies for obesity and cardiometabolic disease.
News
Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity
media576066
Read more
Report
Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity
Helicore's first-in-human study is designed to evaluate the safety and tolerability of HCR-188 in a single and multiple ascending dose studyTop-line safety data anticipated in the second half of 2025 SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWS
Read more
Report
Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half of 2025 Building on existing validation of GIP pathway antagonism with differentiated antibody format and a novel focus on binding
Read more
Report
Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
Read more
Report
Helicore Biopharma advances GIP antagonists for obesity
Helicore Biopharma Inc. has emerged from stealth with $65 million in series A financing and a focus on first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions. The company's portfolio includes GIP antib
Read more
Report
People
Kevin Russ
Executive Officer, Director
Waters Kellogg
Director
Lucas Turner
Director
Joshua Dotson
Director
Holger Koehler
Director
Charles Bridge
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Southbury
United States
HQ
1-10 est. staff
Financials
Total raised
$2M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2020 | $2M | Details |